David James Mcconkey

David James Mcconkey's AcademicInfluence.com Rankings

Philosophy

#4825

World Rank

#7477

Historical Rank

Logic

#2202

World Rank

#3140

Historical Rank

philosophy Degrees

David James Mcconkey

Biology

#6403

World Rank

#9106

Historical Rank

Computational Biology

#111

World Rank

#111

Historical Rank

Molecular Biology

#653

World Rank

#668

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

David James Mcconkey's Degrees

PhD Molecular Biology University of California, San Francisco
Doctorate Medicine Stanford University

Why Is David James Mcconkey Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David James Mcconkey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. (2014) (1297)
Role of Ca2+ in toxic cell killing. (1989) (850)
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. (2009) (785)
Autophagy as a target for anticancer therapy (2011) (727)
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer (2018) (574)
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. (2017) (572)
Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. (1989) (559)
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy (2011) (521)
Calcium‐activated DNA fragmentation kills immature thymocytes (1989) (504)
The role of calcium in the regulation of apoptosis. (1996) (467)
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. (2000) (441)
2,3,7,8-Tetrachlorodibenzo-p-dioxin kills immature thymocytes by Ca2+-mediated endonuclease activation. (1988) (440)
miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy (2009) (413)
Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. (1999) (376)
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. (2015) (360)
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer (2009) (350)
Bax and Bak Promote Apoptosis by Modulating Endoplasmic Reticular and Mitochondrial Ca2+ Stores* (2002) (340)
Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. (1989) (314)
Mechanisms of proteasome inhibitor action and resistance in cancer. (2008) (314)
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells (2009) (313)
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. (2005) (307)
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. (2005) (301)
Apoptosis, cancer and cancer therapy. (1997) (300)
Bcl-2 expression causes redistribution of glutathione to the nucleus. (1998) (298)
Phase I study of recombinant human endostatin in patients with advanced solid tumors. (2002) (292)
Focus on bladder cancer. (2004) (292)
Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. (1999) (288)
Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. (1989) (288)
Calcium-activated DNA fragmentation in rat liver nuclei. (1989) (279)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2018) (277)
Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. (2000) (276)
ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma (2011) (267)
Biochemical determinants of apoptosis and necrosis. (1998) (261)
Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. (1990) (261)
Cellular signalling in programmed cell death (apoptosis). (1990) (261)
ATP stimulates Ca2+ uptake and increases the free Ca2+ concentration in isolated rat liver nuclei. (1989) (259)
Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. (1995) (250)
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. (2006) (249)
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer (2014) (243)
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use (2016) (241)
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. (2002) (238)
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. (2000) (238)
Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols (1997) (226)
Src activation regulates anoikis in human colon tumor cell lines (2002) (220)
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. (2016) (219)
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. (2001) (216)
Bax-mediated Ca2+ Mobilization Promotes Cytochromec Release during Apoptosis* (2002) (214)
Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. (2000) (214)
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. (2007) (210)
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. (2011) (204)
Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. (1991) (204)
Phase II trial of imatinib mesylate in patients with metastatic melanoma (2008) (203)
Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases (2000) (202)
Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias (2004) (201)
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. (2010) (195)
Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. (2002) (193)
Signal transduction pathways in apoptosis. (1994) (187)
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting (2016) (180)
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. (2001) (180)
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. (2003) (175)
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. (1996) (174)
Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. (1996) (172)
2,5‐Di(tert‐butyl)‐1,4‐benzohydroquinone — a novel inhibitor of liver microsomal Ca2+ sequestration (1987) (170)
Stimulation of endogenous endonuclease activity in hepatocytes exposed to oxidative stress. (1988) (170)
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. (2017) (169)
CREB and Its Associated Proteins Act as Survival Factors for Human Melanoma Cells* (1998) (164)
Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. (1996) (160)
Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor (2006) (152)
Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. (2000) (149)
Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. (1996) (147)
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. (2003) (146)
Chemotherapy‐Induced Apoptosis and Bcl‐2 Levels Correlate with Breast Cancer Response to Chemotherapy (2003) (144)
Correlation between cytosolic Ca2+ concentration and cytotoxicity in hepatocytes exposed to oxidative stress. (1988) (139)
Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. (1998) (136)
The role of calcium in the regulation of apoptosis (1996) (133)
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination (2012) (132)
Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. (2000) (127)
Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells (2006) (126)
Gemcitabine-Induced Programmed Cell Death (Apoptosis) of Human Pancreatic Carcinoma Is Determined by Bcl-2 Content (1999) (125)
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. (2001) (125)
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. (2004) (123)
Interleukin 1 inhibits T cell receptor-mediated apoptosis in immature thymocytes. (1990) (123)
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. (2008) (122)
Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. (2016) (117)
Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK Receptors (2004) (117)
The p63 Protein Isoform ΔNp63α Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells (2012) (117)
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. (2005) (116)
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. (2019) (116)
The role of calcium in the regulation of apoptosis. (1997) (116)
Correction: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts (2002) (115)
Apoptosis--molecular mechanisms and biomedical implications. (1996) (115)
Sensitivity to Epidermal Growth Factor Receptor Inhibitor Requires E-Cadherin Expression in Urothelial Carcinoma Cells (2008) (114)
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. (2003) (111)
Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells (2008) (111)
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. (2003) (109)
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia (2006) (106)
Oxygen radical production and thiol depletion are required for Ca(2+)-mediated endogenous endonuclease activation in apoptotic thymocytes. (1995) (106)
Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. (2006) (104)
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. (2008) (102)
Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine (2004) (102)
Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors (2007) (102)
Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. (2018) (101)
Role of P38 MAPK, AP-1, and NF-κB in interleukin-1β-induced IL-8 expression in human vascular smooth muscle cells (2002) (97)
New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine (2011) (97)
Origins of Bladder Cancer. (2016) (95)
Molecular Subtypes of Bladder Cancer (2018) (95)
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. (2007) (94)
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas (2004) (89)
A phase I surrogate endpoint study of SU6668 in patients with solid tumors (2004) (89)
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. (2011) (89)
Signal Transduction Pathways in Apoptosis (1996) (88)
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor zenografts (2004) (88)
Surrogate markers in antiangiogenesis clinical trials (2003) (87)
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. (2004) (87)
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. (2005) (86)
Cellular signaling in thymocyte apoptosis. (1992) (84)
Calcium‐dependent DNA fragmentation in human synovial cells exposed to cold shock (1990) (83)
Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer (2013) (82)
NK cell‐induced cytotoxicity is dependent on a Ca2+ increase in the target (1990) (81)
Killing of immature CD4+CD8+ thymocytes in vivo by anti‐CD3 or 5′‐(N‐ethyl)‐carboxamido‐adenosine is blocked by glucocorticoid receptor antagonist RU‐486 (1993) (79)
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer (2018) (79)
Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting (2013) (78)
Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines (2009) (78)
Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells (2004) (77)
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes (2020) (77)
Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2 (1997) (76)
Ras signaling in tumor necrosis factor‐induced apoptosis. (1996) (76)
p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers (2012) (75)
Apoptosis: a general comment (1991) (75)
CD3 zeta dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. (1992) (74)
Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer (2004) (74)
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. (2006) (74)
Nitric Oxide–Dependent Activation of P53 Suppresses Bleomycin-Induced Apoptosis in the Lung (2000) (73)
Molecular correlates of gefitinib responsiveness in human bladder cancer cells (2007) (73)
Signalling and Chromatin Fragmentation in Thymocyte Apoptosis (1994) (72)
Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. (2012) (72)
Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials (2019) (72)
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. (2001) (72)
Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma (2009) (71)
Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment (2000) (70)
Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines (2008) (69)
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. (2007) (69)
Assessment of Luminal and Basal Phenotypes in Bladder Cancer (2020) (68)
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy (2008) (67)
Calcium-dependent, Interleukin 1β-converting Enzyme Inhibitor-insensitive Degradation of Lamin B1 and DNA Fragmentation in Isolated Thymocyte Nuclei* (1996) (67)
Role of calcium in toxic and programmed cell death. (1991) (67)
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells (2009) (65)
Rapid turnover of endogenous endonuclease activity in thymocytes: effects of inhibitors of macromolecular synthesis. (1990) (64)
The CD3 zeta cytoplasmic domain mediates CD2-induced T cell activation (1992) (63)
Disruption of Mekk2 in Mice Reveals an Unexpected Role for MEKK2 in Modulating T-Cell Receptor Signal Transduction (2002) (63)
Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy (2006) (62)
Adenovirus-mediated wild-typep53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer (1998) (61)
Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts (2004) (61)
Intravesical Ad-IFNα Causes Marked Regression of Human Bladder Cancer Growing Orthotopically in Nude Mice and Overcomes Resistance to IFN-α Protein (2004) (61)
Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. (2005) (60)
Inhibition of proliferation of PC3 cells by the branched‐chain fatty acid, 12‐methyltetradecanoic acid, is associated with inhibition of 5‐lipoxygenase (2003) (60)
Ca2+-activated mechanisms in cell killing. (1989) (59)
Identification of Differential Tumor Subtypes of T1 Bladder Cancer. (2020) (59)
New insights into subtypes of invasive bladder cancer: considerations of the clinician. (2014) (58)
Cyclic AMP potentiates glucocorticoid‐induced endogenous endonuclease activation in thymocytes 1 (1993) (58)
Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. (1997) (57)
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response. (2003) (55)
Interferon-α Induces TRAIL Expression and Cell Death Via an IRF-1-Dependent Mechanism in Human Bladder Cancer Cells (2007) (55)
Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts (2004) (54)
Transcription Factor AP-2α Is Preferentially Cleaved by Caspase 6 and Degraded by Proteasome during Tumor Necrosis Factor Alpha-Induced Apoptosis in Breast Cancer Cells (2001) (54)
Apoptosis in Mycobacterium tuberculosis infection in mice exhibiting varied immunopathology (2000) (53)
CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. (1996) (53)
The integrated stress response and proteotoxicity in cancer therapy. (2017) (53)
Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss. (2000) (53)
Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines (2006) (52)
Molecular Profiling of Direct Xenograft Tumors Established from Human Pancreatic Adenocarcinoma After Neoadjuvant Therapy (2012) (51)
Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. (2015) (51)
Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer (2017) (50)
Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis (2010) (49)
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. (2009) (49)
Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. (2003) (49)
Prognostic factors in resectable pancreatic cancer: p53 and Bcl-2 (1999) (48)
Three-dimensional organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells (2018) (47)
Predictive biomarkers for drug response in bladder cancer (2019) (47)
Ca2+-activated mechanisms in toxicity and programmed cell death (1988) (47)
Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells (2006) (47)
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia (2007) (47)
Micropapillary bladder cancer: current treatment patterns and review of the literature. (2014) (46)
Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma (2018) (46)
Adenoviral Transfer of mda-7 Leads to BAX Up-regulation and Apoptosis in Mesothelioma Cells, and is Abrogated by Over-expression of BCL-XL (2002) (45)
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells (2006) (45)
Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. (1998) (44)
100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19 (2021) (44)
p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells (2002) (43)
BCL2 expression correlates with metastatic potential in pancreatic cancer cell lines (2001) (43)
Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. (2003) (42)
Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion. (2000) (42)
Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. (2000) (42)
In vivo intracellular signaling as a marker of antiangiogenic activity. (2001) (41)
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. (2005) (41)
The regulation of apoptosis in thymocytes. (1994) (41)
Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells (2005) (41)
Bcl-2 protects cells from cytokine-induced nitric-oxide-dependent apoptosis (1996) (41)
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior (2017) (40)
Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). (2020) (40)
Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors (2004) (40)
Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. (2004) (39)
Differential regulation of endogenous endonuclease activation in isolated murine fibroblast nuclei by ras and bcl-2. (1995) (39)
Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. (2002) (39)
Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer (2017) (39)
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. (2006) (38)
Bladder cancer stem cells. (2010) (38)
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancer. (2012) (37)
The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures (2020) (37)
Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells (2013) (37)
Inhibition of I‐Ad‐, but not Db‐restricted peptide‐induced thymic apoptosis by glucocorticoid receptor antagonist RU486 in T cell receptor transgenic mice (1996) (37)
Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells (2010) (37)
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) kills glucocorticoid-sensitive thymocytes in vivo. (1989) (36)
Genetic subtypes of invasive bladder cancer (2015) (35)
Phosphorylation of multiple CD3 zeta tyrosine residues leads to formation of pp21 in vitro and in vivo. Structural changes upon T cell receptor stimulation. (1992) (35)
Combination therapy with IFN-α plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells (2006) (35)
Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. (2020) (34)
Targeting Signaling Transduction Pathways in Bladder Cancer (2015) (34)
Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer (2017) (34)
Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2016) (33)
Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. (2013) (33)
Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. (1995) (33)
Targeting EGFR in bladder cancer. (2007) (33)
Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells. (2002) (32)
Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer (2016) (32)
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) (2021) (31)
The human retinoblastoma gene product suppresses ceramide-induced apoptosis in human bladder tumor cells. (1996) (30)
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. (2018) (29)
Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells (2012) (29)
Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. (2007) (26)
Calcium and cyclosporin A in the regulation of apoptosis. (1995) (26)
Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. (2019) (26)
Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes (2021) (26)
Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. (2014) (26)
Novel therapies for pancreatic adenocarcinoma (2004) (26)
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer. (2019) (25)
Phosphatidylserine externalization during differentiation-triggered apoptosis of erythroleukemic cells (1999) (25)
Anoikis is regulated by BCL‐2‐independent pathways in human prostate carcinoma cells (2002) (25)
Thymocyte apoptosis by glucocorticoids and cAMP. (1995) (25)
Differential signal transduction via T-cell receptor CD3 zeta 2, CD3 zeta-eta, and CD3 eta 2 isoforms. (1991) (25)
Increased Apoptosis in Metastatic Human Colonic Adenocarcinomas (2002) (25)
Calcium flux measurements in apoptosis. (2001) (24)
Intrinsic subtypes and bladder cancer metastasis (2016) (24)
Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. (2011) (24)
Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. (2019) (24)
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes (2021) (24)
CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer (2018) (23)
Proteasome and HDAC: who's zooming who? (2010) (22)
Mutational Landscape and Environmental Effects in Bladder Cancer (2020) (22)
A multiplexed, particle‐based flow cytometric assay identified plasma matrix metalloproteinase‐7 to be associated with cancer‐related death among patients with bladder cancer (2010) (21)
Co-receptor (CD4/CD8) engagement enhances CD3-induced apoptosis in thymocytes. Implications for negative selection. (1994) (21)
A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin (2013) (21)
Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. (2007) (21)
Update on bladder cancer molecular subtypes (2020) (20)
Endothelial cell apoptosis is inhibited by a soluble factor secreted by human colon cancer cells (2001) (20)
Adenoviral-mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marked bystander effects (2007) (18)
Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE) (2004) (18)
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer (2022) (18)
p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells (2012) (17)
HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells (2017) (17)
Bortezomib paradigm shift in myeloma. (2009) (16)
Clinical implications of molecular subtyping in bladder cancer. (2019) (16)
Quantitation of DNA fragmentation using fiberglass filters. (1989) (15)
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. (2011) (15)
Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis (2016) (15)
Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer? (2019) (14)
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study (2021) (13)
Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line. (2018) (13)
Phase II Study of the Antiangiogenic Agent SU 5416 in Patients with Advanced Soft Tissue Sarcomas (2004) (13)
The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside (2018) (13)
RETRACTED ARTICLE: Targeting EGFR in bladder cancer (2007) (13)
Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. (2020) (13)
Novel therapies for pancreatic adenocarcinoma (2004) (13)
Antiangiogenic tumor therapy. (2003) (13)
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon α: possible use as a surrogate marker 1 (2009) (12)
Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. (2017) (12)
Therapy-induced apoptosis in primary tumors. (2007) (12)
Role of Calcium in Oxidative Cell Injury (1989) (11)
Generation of natural killer cells from both Fc gamma RII/III+ and Fc gamma RII/III- murine fetal liver progenitors. (1993) (11)
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) (2021) (11)
Apoptotic and anti-vascular activity of imatinib in GIST patients (2005) (11)
Bax and Bak are required for cytochrome c release during arsenic trioxide-induced apoptosis (2005) (11)
Generation of natural killer cells from both FcγRII/III+ and FcγRII/III- murine fetal liver progenitors (1993) (10)
S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer. (2017) (10)
Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. (2017) (10)
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer (2020) (10)
Measurement of changes in intracellular calcium during apoptosis. (2004) (9)
Organoid culture of bladder cancer cells (2018) (9)
Oncogene regulation of endonuclease activation in apoptosis. (1995) (9)
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation (2019) (9)
Cycloheximide-induced apoptosis in melanoma cells derived from regressing cutaneous tumours of Sinclair swine. (1996) (9)
A novel role for a familiar protein in apoptosis induced by proteasome inhibition. (2008) (9)
Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation (2009) (9)
Emerging drugs for targeted therapy of bladder cancer (2007) (8)
Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248 (2005) (8)
Inhibition of the Pan-Bcl-2 Family by the Small Molecule GX15-070 Induces Apoptosis in Mantle Cell Lymphoma (MCL) Cells and Enhances the Activity of Two Proteasome Inhibitors (NPI-0052 and Bortezomib), and Doxorubicin Chemotherapy. (2006) (8)
A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC. (2018) (8)
A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. (2021) (8)
Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer (2020) (8)
AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo. (2006) (7)
Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines. (2019) (7)
Oncology clinical trials (2013) (7)
Mechanisms of cell toxicity the thiol calcium hypothesis (1988) (7)
Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments. (2020) (7)
Expression Analysis of Same-Patient Metachronous and Synchronous Upper-Tract and Bladder Urothelial Carcinoma. (2021) (6)
Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature. (2021) (6)
Proteasome Inhibitors Induce Apoptosis in Glucocorticoid-Resistant Chronic (6)
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. (2019) (6)
Unique somatic variants in the DNA from urine exosomes of bladder cancer patients (2021) (6)
Expression of nectin-4 in bladder cancer with variant histology. (2020) (6)
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? (2008) (5)
Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells (2017) (5)
Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. (2017) (5)
Control of HIF-1A Expression by eIF2A Phosphorylation-Mediated Translational Repression (2009) (5)
Recombinant BCG overexpressing STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer (2020) (5)
Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia. (1999) (5)
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far? (2021) (5)
Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL. (2004) (5)
Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy (2005) (5)
RAIDDing ER stress for oncolytic viral therapy. (2011) (5)
Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10. (2015) (5)
In-Frame cDNA Library Combined with Protein Complementation Assay Identifies ARL11-Binding Partners (2012) (4)
Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin. (2015) (4)
Regulation and Function of Detachment-Induced Cell Death (Anoikis) in Cancer Progression and Metastasis (2007) (4)
Bridging the Gap in Upper Tract Urothelial Carcinoma. (2015) (4)
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide. (2020) (4)
Cellular signaling in cell death. (1993) (4)
Molecular Characterization of Pancreatic Cancer Cell Lines (2010) (4)
Programmed cell death in tumours and tissues (1991) (4)
Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695). (2020) (4)
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer (2020) (4)
Overexpression of CD3 eta during thymic development does not alter the negative selection process. (1993) (4)
Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. (2012) (4)
The origin of bladder cancer from mucosal field effects (2021) (4)
The basal subtype to predict clinical benefit from neoadjuvant chemotherapy: Final results from a phase II clinical trial of DDMVAC + bevacizumab. (2015) (4)
Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients. (2015) (4)
A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer (2021) (4)
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial (2021) (3)
SIU–ICUD consultation on bladder cancer: basic science (2018) (3)
Development of a translational medicine protocol for an NCTN genitourinary clinical trial: Critical steps, common pitfalls and a basic guide to translational clinical research. (2019) (3)
Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment (2020) (3)
γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer (2021) (3)
Subtyping Bladder Cancers: Biology vs Bioinformatics. (2018) (3)
Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome. (2020) (3)
Glucagon activation of the thiol:protein disulfide oxidoreductase in isolated, rat, hepatic microsomes. (1986) (3)
Apoptosis and Taxol Therapy (2002) (3)
BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer (2021) (3)
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. (2020) (3)
patients with chronic lymphocytic leukemia inducer of apoptosis than bortezomib in lymphocytes from The proteasome inhibitor NPI-0052 is a more effective Updated (2006) (3)
Lentiviral interferon: A novel method for gene therapy in bladder cancer (2018) (2)
149 INVITED Are there rational novel targets for pancreatic cancer therapeutics? Observations from the M.D. Anderson Cancer Center SPORE in Pancreatic Cancer (2007) (2)
SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up. (2022) (2)
Molecular characterization of neuroendocrine bladder cancer. (2020) (2)
838: Adenoviral-Mediated IFNα2B Expression Suppresses Proangiogenic Factors in Bladder Cancer (2006) (2)
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. (2023) (2)
Apoptosis: Signaling pathways in pancreatic cancer pathogenesis (2018) (2)
Biology and therapy of urological cancer metastasis (2016) (2)
Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project (2015) (2)
Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. (2017) (2)
ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers. (2019) (2)
Limited Upstaging in Luminal Subtype Tumors: Ready for Clinical Practice? (2019) (2)
The Histone Deacetylase Inhibitor Vorinostat Induces Apoptosis in T-Cell Lymphoma Cell Lines and Synergizes with Bortezomib. (2008) (2)
Combined next generation sequencing and flow cytometry analysis of an anti-PD-L1 partial responder over time: An exploration into mechanisms of PD-L1 activity and resistance (2017) (2)
20S ways to apoptosis. (2008) (2)
Velcade displays promising activity in primary effusion lymphoma cells (2005) (2)
Epidermal Growth Factor Receptor Blockade with C 225 Plus Gemcitabine Results in Regression of Human Pancreatic Carcinoma Growing Orthotopically in Nude Mice by Antiangiogenic Mechanisms 1 (2000) (2)
206 POSTER EGFR and PDGFR crosstalk may dictate the resistance to EGFR therapy in bladder cancer (2006) (2)
The Molecular, the Bad, and the Ugly: Preventing Bladder Cancer via mTOR Inhibition (2009) (2)
Pancreatic Cancer Cells Kinase and Induces Apoptosis via ER Stress in Human Bortezomib Inhibits PKR-Like Endoplasmic Reticulum ( ER ) (2005) (2)
Nuclear factor-K B maintains TRAIL resistance in human pancreatic cancer cells (2006) (2)
MP83-12 IN VITRO EFFECTS OF INTERFERON ALPHA IN BLADDER CANCER: IMMUNE CHECKPOINT EXPRESSION AND MICRORNA AND MRNA GENOMIC PROFILING (2016) (2)
Effects of thiazolidinedione in patients with active bladder cancer (2018) (2)
Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. (2022) (2)
apoptosis in response to the combination of bortezomib and SAHA Myc regulates aggresome formation, the induction of Noxa, and (2013) (2)
Abstract LB-472: p63 inhibits epithelial - mesenchymal transition by promoting the expression of miR205 in human bladder cancer cells (2012) (2)
Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer (2009) (2)
Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy. (2021) (2)
Abstract 970: Gender-specific stratification of survival following immune checkpoint inhibitor therapy based on intratumoral expression of a B cell gene signature (2021) (1)
Abstract A1-68: The long noncoding RNA SNHG18 promotes PPARγ function and luminal gene expression in muscle-invasive bladder cancer (2015) (1)
Resistance to tumor necrosis factor-induced apoptosis in mouse fibroblasts is a genetically dominant phenotype. (1996) (1)
A Festschrift in Honor of Edward M. Messing, MD, FACS (2018) (1)
A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. (2018) (1)
Cancer stem cells and intrinsic subtypes in bladder cancer (2015) (1)
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. (2022) (1)
Resistance to Apoptosis in Cancer Therapy (2005) (1)
Abstract 4589: SRC drives invasion of luminal, but not basal, bladder cancer (2019) (1)
MP61-07 IDENTIFICATION OF DISTINCT BASAL AND LUMINAL SUBSETS OF HUMAN BLADDER CANCERS WITH DIFFERENT SENSITIVITIES TO FRONTLINE CHEMOTHERAPY (2014) (1)
Does it matter whether a T1 high-grade tumor is molecularly classified? (2019) (1)
The CD3~" Cytoplasmic Domain Mediates CD2-induced T Cell .Activation (2003) (1)
Abstract P174: YAP1 drives immune suppression in urothelial carcinoma of bladder (2021) (1)
Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review (2021) (1)
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. (2020) (1)
CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer (2018) (1)
Molecular Biology of Bladder Cancer: Potential Implications for Therapy. (2021) (1)
Cancer Biology.Fourth Edition. ByRaymond W. Ruddon. Oxford and New York: Oxford University Press. $98.50 (hardcover); $69.50 (paper). xiv + 530 p. + 24 pl.; ill.; index. 978‐0‐19‐517543‐1 (hc); 978‐0‐19‐517544‐8 (pb). 2007. (2009) (1)
THE EFFECT OF INTRINSIC SUBTYPE ON RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER: PD62‐03 (2017) (1)
Strategies for Chemoprevention in Pancreatic Cancer (2005) (1)
506 The tumor immune microenvironment of metastatic osteosarcoma is marked by lymphocyte exclusion and impacts patient progression-free survival (2020) (1)
Risk group stratification in patients with micropapillary bladder cancer treated with radical cystectomy and/or neoadjuvant chemotherapy. (2015) (1)
Microenvironment and Immunology Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT 1 and Autotaxin (2012) (1)
Erratum: Phase I study of bortezomib in refractory or relapsed acute leukemias (Clinical Cancer Research (May 15, 2004) 10 (3371-3377)) (2004) (1)
THE MITOTOIC SPINDLE APPARATUS INHIBITOR AZD4877 HOLDS PROMISE AS A NOVEL THERAPEUTIC OPTION AGAINST HUMAN BLADDER CANCER (2009) (1)
BASAL AND LUMINAL IMMUNOHISTOCHEMICAL PHENOTYPES IN MUSCLE INVASIVE BLADDER UROTHELIAL CARCINOMAS (MIBC) TREATED WITH NEOADJUVANT CHEMOTHERAPY (NAC): MP58‐05 (2017) (1)
PD42-08 NOVEL COMBINATION THERAPY USING LENTIVIRAL INTERFERON AND IMMUNE CHECKPOINT BLOCKADE FOR TREATMENT OF BLADDER CANCER IN A MURINE MODEL (2020) (1)
The Novel, Orally Active Proteasome Inhibitor, NPI-0052, Induces Apoptosis in Leukemia Lymphoma Cell Lines and Patient Specimens. (2005) (1)
Abstract CT241: Gene expression profiling in the context of neoadjuvant chemotherapy with DDMVAC+B (dose dense methotrexate, vinblastine, doxorubicin, cisplatin, and bevacizumab) can predict clinical outcomes and tumor biology (2014) (1)
Relationship between high microRNA-200C expression and the risk of death from disease in muscle-invasive urothelial carcinoma of the bladder. (2012) (1)
LIMD2 EXPRESSION IS UPREGULATED IN BLADDER CANCER LYMPH NODE METASTASES, CORRELATES WITH THE AGGRESSIVE BASAL MOLECULAR PHENOTYPE, AND IS IMPLICATED IN BLADDER CANCER METASTASIS.: MP98‐07 (2017) (1)
The hotspot mutational landscape of upper tract and bladder urothelial cancers and correlation to survival. (2016) (1)
A novel phase I trial design featuring a two-dimensional dose-finding algorithm optimizing the dose of gemcitabine and doxorubicin with bortezomib in metastatic urothelial carcinoma (UC). (2013) (1)
Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer (2021) (1)
PD-L1 and PD-1 expression patterns in patients with NMIBC undergoing intravesical BCG (2017) (0)
Bladder Cancer: Non-invasive III (2022) (0)
MOLECULAR CHARACTERIZATION OF N‐METHYL‐N‐NITROSOUREA‐INDUCED BLADDER UROTHELIAL TUMOR IN RATS: MP54‐12 (2018) (0)
Feasibility of digital pathology of circulating tumor cells with morphologic analysis in localized bladder cancer. (2020) (0)
478 POSTER Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated XIAP expression (2006) (0)
57 POSTER Correlation of receptor tyrosine kinase (RTK) activity and paoptosis with response to sunitinib treatment in patients with gastrointestinal stromal tumor (GIST) (2006) (0)
Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer (2022) (0)
Differential expression of FOXF1 in bladder cancer metastases and association with established bladder cancer subtypes. (2016) (0)
Characterizing molecular subtypes of high-risk nonmuscle-invasive bladder cancer in African American patients. (2022) (0)
563 Distinct effects of proteasome inhibition by a novel inhibitor in lymphoid cells (2004) (0)
MP59-09 CHARACTERIZING MOLECULAR SUBTYPES OF HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER IN AFRICAN AMERICAN PATIENTS (2022) (0)
The indoleamine 2,3 dioxygenase pathway drives intratumoral B cell maintenance (2021) (0)
PD47-07 A GENETICALLY MODIFIED BCG THAT OVEREXPRESSES A STING AGONIST SHOWS ENHANCED ANTITUMOR EFFICACY MEDIATED BY AN M1 MACROPHAGE POLARIZATION WITH POTENTIATION OF TRAINED IMMUNITY (2020) (0)
Assessment of Luminal and Basal Phenotypes in Bladder Cancer (2020) (0)
GENE EXPRESSION PROFILING DISTINGUISHES BETWEEN DRUG-SENSITIVE AND RESISTANT PANCREATIC CANCER CELL LINES (2008) (0)
MP47-04 REFINING SELECTION CRITERIA FOR NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: COMBINING CLINICAL RISK FEATURES AND INTRINSIC MOLECULAR SUBTYPES (2018) (0)
Preclincial Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer (2017) (0)
Oncologic outcomes in patients with residual invasive upper tract urothelial carcinoma following neoadjuvant chemotherapy. (2023) (0)
Tumor Immune Microenvironment in Response to Radiotherapy vs BCG in a Murine Model of Bladder Cancer (2020) (0)
The origin of bladder cancer from mucosal field effects (2022) (0)
Proteolytic cleavage of vimentin during glucocorticoid-induced apoptosis (1996) (0)
Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging requires correction for hypoperfusion, hypoxia and necrosis. (2007) (0)
MP18-01 INCIDENCE OF LOWER PATHOLOGIC STAGE IN PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY FOR HIGH-RISK UPPER TRACT UROTHELIAL CARCINOMA (2018) (0)
Abstract 3253: Next-gen STING-agonist like BCG confers enhanced immunogenicity and antitumor efficacy in vitro and in vivo (2019) (0)
Atezolizumab with platinum and etoposide chemotherapy followed by cystectomy for patients with localized small cell neuroendocrine bladder cancer. (2023) (0)
Caspase-mediated cleavage of p21 is associated with apoptosis in prostate and bladder cancer cells treated with TRAIL plus bortezomib in vitro (2005) (0)
Abstract 1836: Global gene expression profiles from bladder tumor FFPE samples (2016) (0)
PD42-01 RESIDUAL MUSCLE-INVASIVE DISEASE AT CYSTECTOMY IS NOT ACCURATELY PREDICTED BY POST-CHEMOTHERAPY RESTAGING PROTOCOLS INCLUDING DNA DAMAGE RESPONSE GENE MUTATION ANALYSIS (2020) (0)
Lentiviral interferon with immune checkpoint blockade: A novel method for gene therapy in bladder cancer. (2020) (0)
PD47-06 INTRATUMORAL ADMINISTRATION OF A RECOMBINANT BCG OVEREXPRESSING A STING AGONIST CAUSES INCREASED EXPANSION OF IFN-γ PRODUCING CD4 + T CELLS IN SOLID TUMORS (2020) (0)
Molecular characterization of field effects and their progression to clinically evident bladder cancer (2017) (0)
A phase I clinical trial of recombinant human endostatin in patients with solid tumors Surrogate analyses to determine a biologically effective dose (2001) (0)
Novel Approach to Interferon-Alpha Gene Therapy for Bladder Cancer in a Mouse Model (2004) (0)
Table of Contents (1996) (0)
Abstract 2765: The indoleamine 2,3 dioxygenase-1 pathway drives intratumoral B cell maintenance (2021) (0)
Remarkable difference between 3D and 2D cultures of bladder cancer cells in response to drugs: A concrete example for importance of 3D culture (2019) (0)
Progression to sarcomatoid bladder cancer is associated with dysregulation of chromatin remodelling and cell cycle circuits (2017) (0)
MP54-05 EVALUATING INTRAVESICAL NADOFARAGENE FIRADENOVEC AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A PHASE 3 TRIAL (2022) (0)
Retraction Note: Targeting EGFR in bladder cancer (2012) (0)
PA1 Assessing the Progression of the UK NHS Health Care Reforms and the Impact on Health Care Delivery (2012) (0)
Abstract 3979: Immune correlates of pathologic response in bladder cancer patients undergoing neoadjuvant chemotherapy (2017) (0)
Abstract B101: Design and optimization of a new series of HSP70 inhibitors for use in the treatment of pancreatic cancer. (2013) (0)
Identification of lineage-specific transcription factor defined subtypes in small cell/neuroendocrine bladder cancer. (2023) (0)
Abstract 234: Fibroblast growth factor receptor (FGFR)-3 as a suitable target in bladder cancer (2011) (0)
Pancreatic Cancer Cell Lines Activation and Sensitivity to Gefitinib ( Iressa ) in Human Constitutive Epidermal Growth Factor Receptor Pathway Expression Drives α Transforming Growth Factor Updated (2006) (0)
Chronic Lymphocytic Leukemic Lymphocytes Proteasome Inhibitors Induce Apoptosis in Glucocorticoid-Resistant (2010) (0)
MP38-06 IDENTIFICATION OF NOVEL IMMUNE BASAL SUBTYPES IN MUSCLE INVASIVE BLADDER CANCER (2019) (0)
Gefitinib enhances TRAIL sensitivity in bladder cancer cells through an Akt-dependent mechanism (2006) (0)
Abstract 4973: The immunosuppressive tumor microenvironment of metastatic osteosarcoma inhibits the cytotoxic effect of tumor-infiltrating lymphocytes (2019) (0)
MP57-02 “NEXT-GEN STING-AGONIST LIKE BCG CONFERS ENHANCED IMMUNOGENICITY AND ANTITUMOR EFFICACY IN VITRO AND IN VIVO” (2019) (0)
Abstract IA03: Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneity (2020) (0)
PD53-11 DIVERGENT THERAPEUTIC OUTCOMES OF STING AGONIST ADU-S100 IN INTRATUMORAL AND INTRAVESICAL TREATMENT REGIMENS IN SYNGENEIC MURINE MB49 AND IN THE N-METHYL-N-NITROSOUREA (MNU) RAT MODEL OF UROTHELIAL CARCINOMA (2022) (0)
E-CADHERIN EXPRESSION POTENTIATES ERLOTINIB TREATMENT IN BLADDER CANCER (2008) (0)
Award Number: W81XWH-04-1-0182 TITLE: Regulation of calcium fluxes and apoptosis by BCL-2 family proteins in prostate cancer cells (2006) (0)
Augmentation of urothelial cancer cells' response to gemcitabine and cisplatin by a Smac mimetic. (2013) (0)
Predictive impact of intrinsic bladder cancer subtypes on survival after radical cystectomy (2017) (0)
558 POSTER Epithelial mesenchymal transition (EMT) and hMena expression as determinants of sensitivity of pancreatic adenocarcinoma (PDAC) cell lines to EGFR tyrosine kinase Inhibitors (TKI) (2006) (0)
MP83-14 GENOMIC EXPRESSION EVIDENCE FOR ANDROGEN RECEPTOR AXIS ACTIVATION IN UROTHELIAL CARCINOMA: DATA FROM THE CANCER GENOME ATLAS (2016) (0)
Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy (2017) (0)
PD33-11 NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER: P53-NESS IS ASSOCIATED WITH CHEMO-RESISTANCE AND UNFAVORABLE OUTCOME (2016) (0)
Induces Tumor and Endothelial Cell Apoptosis Inhibits the Growth of Colon Cancer Liver Metastasis and Receptor for Vascular Endothelial Growth Factor Receptor Antiangiogenic Therapy Targeting the Tyrosine Kinase Updated (1999) (0)
Abstract 894: Genetic variations in the angiogenesis pathway modulate clinical outcomes of bladder cancer (2010) (0)
2 Resistance to Apoptosis in Cancer Therapy (2017) (0)
Molecular characterization of N-methyl-N-nitrosourea-induced bladder urothelial tumor in rats (2019) (0)
Repression of the Androgen Receptor by WT1, a Tumor Suppressor Gene (2001) (0)
Proteasome Inhibition and Apoptosis (2004) (0)
The Many Faces of Muscle-Invasive Bladder Cancer: Histopathological and Molecular Characterization. (2023) (0)
The ATP Switch in Apoptosis (2002) (0)
Abstract B70: Histone deacetylase inhibitors reverse EMT phenotype and chemoresistance in pancreatic cancer cell lines (2009) (0)
MOLECULAR SUBTYPE CLASSIFICATION OF N‐METHYL‐N‐NITROSOUREA‐INDUCED UROTHELIAL CANCERS AND EX‐VIVO CULTURED SPHEROIDS IN RATS.: MP48‐19 (2017) (0)
Cell Cycle Dependence of TRAIL Sensitivity in Prostate Cancer Cells (2006) (0)
PD53-01 MOLECULAR SUBTYPING OF N-METHYL-N-NITROSOUREA (MNU) RAT MODEL OF UROTHELIAL CARCINOMA REVEALS BOTH LUMINAL AND BASAL SIGNATURES (2022) (0)
Local Mate Competition Experimental Evolution of Reduced Sex Ratio Adjustment Under (2011) (0)
Book Review:Apoptosis and Cancer Chemotherapy John A. Hickman, Caroline Dive (2000) (0)
Abstract PR09: Gene expression profiling in wild-type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab (2020) (0)
Use of P63 expression to define a lethal subset of muscle-invasive bladder cancers. (2011) (0)
Regulation of Calcium Fluxes and Apoptosis by BCL-2 Family Proteins in Prostate Cancer Cells (2006) (0)
Differential signal transduction via T-cell receptor CD 3 ' 2 , CD 3 C-, v , and CD 3 ' q 2 isoforms ( Ca 2 + mobilization / phosphatidylinositol turnover / protein tyrosine kinase / interleukin 2 production ) (0)
MOLECULAR SUBTYPES OF MUSCLE INVASIVE BLADDER CANCER ARE RELATED TO BENEFIT FROM NEOADJUVANT CHEMOTHERAPY: DEVELOPMENT OF A SINGLE SAMPLE PATIENT ASSAY: MP34‐01 (2017) (0)
Abstract 1592: Bladder cancer circulating tumor cell concentration fluctuates in the absence of systemic therapy or surgery (2018) (0)
gamma RII/III- murine fetal liver progenitors Generation of natural killer cells from both Fc gamma RII/III+ and Fc (2011) (0)
A STAT3- and p63-dependent transcriptional network to define a lethal basal subset of human bladder cancers. (2013) (0)
Correction: Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines (Cancer Research (2006) 66, 7, (3802-3812)) (2010) (0)
Inhibition of Angiogenesis and regression of human pancreatic cancer by blockade of egf-r signal transduction in combination with gemcitabine (2001) (0)
The proteasome inhibitor bortezomib inhibits tumor cell growth and induces apoptosis by activating the cJUN NH2-terminal kinase (JNK) pathway in pancreatic cancer (2004) (0)
Relationship between high microRNA-200C expression and the risk of death from disease in muscle-invasive urothelial carcinoma of the bladder. (2012) (0)
1713 A MULTIPLEXED, PARTICLE BASED FLOW CYTOMETRIC ASSAY IDENTIFIED MMP7 TO BE ASSOCIATED WITH CANCER RELATED DEATH AMONG PATIENTS WITH BLADDER CANCER (2010) (0)
Corrigendum to “Identification of Differential Tumor Subtypes of T1 Bladder Cancer” [Eur. Urol. 78 (2020) 533–537] (2021) (0)
Award Number: W81XWH-06-1-0059 TITLE: Cell cycle dependence of TRAIL sensitivity in prostate cancer cells (2007) (0)
1363 TARGETING FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)-3 IN BLADDER CANCER: PRE-CLINICAL PROOF OF PRINCIPLE (2011) (0)
Identification of bladder cancer biomarkers by genomic approaches (2016) (0)
Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment (2001) (0)
MP18-08 GENOMIC ANALYSIS OF SAME-PATIENT METACHRONOUS UPPER-TRACT AND BLADDER UROTHELIAL CARCINOMA (2018) (0)
malignant B cells and overcome fludarabine resistance in CLL Targeting endoplasmic reticulum protein transport: a novel strategy to kill (2013) (0)
425 POSTER Biological role of the CREB/COX-2 pathway in the regulation of human pancreatic cancer proliferation and survival (2006) (0)
Improving immune-gene therapy for bladder cancer (2017) (0)
MP05-02 CTC AND CTDNA ASSAYS REVEAL COMPLIMENTARY INFORMATION FOR METASTATIC UROTHELIAL CANCER PATIENTS (2019) (0)
EPIGENETIC PRIMING WITH 5‐AZACITIDINE INCREASES SENSITIVITY OF BLADDER CANCER CELLS TO CHEMOTHERAPEUTIC AGENTS: MP65‐20 (2017) (0)
Advances in Brief Therapy of Human Pancreatic Carcinoma Implants by Irinotecan and the Oral Immunomodulator JBT 3002 Is Associated with Enhanced Expression of Inducible Nitric Oxide Synthase in Tumor-infiltrating Macrophages 1 (2000) (0)
MP66-07 BCG INVOKES SUPERIOR STING-MEDIATED INNATE IMMUNE RESPONSE OVER RADIOTHERAPY IN A CARCINOGEN MURINE MODEL OF UROTHELIAL CANCER (2021) (0)
Abstract 1611: Intravesical BCG induces CD4 T Cell expansion in an immune competent model of bladder cancer (2017) (0)
Abstract 3689: Identification of candidate therapeutic targets in BCG unresponsive bladder cancer- inflammatory subtypes of BCG unresponsive bladder cancer (2018) (0)
THREE‐DIMENSIONAL ORGANOID CULTURE REVEALS INVOLVEMENT OF WNT/&bgr;‐CATENIN PATHWAY IN PROLIFERATION OF BLADDER CANCER CELLS: MP54‐06 (2018) (0)
At least two ways to apoptose (1996) (0)
Cancer Therapy : Preclinical Effects of mTOR Inhibitor Everolimus ( RAD 001 ) on Bladder Cancer Cells (2011) (0)
MAGNITUDE OF STING SIGNALING DETERMINES ANTITUMOR OUTCOMES, AND CD8 D T CELL MEMORY BY BCG-STING IN UROTHELIAL TUMORS USING A BIFIDOBACTRERIUM VECTOR OF (2022) (0)
MP66-06 STING PATHWAY MOLECULES DO NOT PREDICT BCG RESPONSE IN NON-MUSCLE INVASIVE BLADDER CANCER (2021) (0)
Triona Ni Chonghaile Response to Cytotoxic Chemotherapy Pretreatment Mitochondrial Priming Correlates with Clinical (2011) (0)
Abstract 307: Germline ablation of candidate forerunner gene, P2RY5, in a mouse model. (2013) (0)
SU‐FF‐I‐87: High Frequency Ultrasound To Monitor Murine Orthotopic Bladder Cancer Model : An Alternative To Magnetic Resonance Imaging (2006) (0)
Urological cancers. Preface. (2009) (0)
Proteotoxic Stress and Proteasome Inhibitor Efficacy and Resistance (2014) (0)
Abstract 4427: Apoptosis, autophagy and ATP: The dynamic interaction of cellular ATP and drug resistance in MET amplified gastric cancer (2015) (0)
Abstract 3920: EphA2 transcription is regulated by activation of Ras / MEK2 / cytoplasmic ERK pathway in pancreatic cancer (2010) (0)
PD51-03 DIGITAL PATHOLOGY OF CIRCULATING TUMOR CELLS WITH MORPHOLOGIC ANALYSIS IS FEASIBLE IN LOCALIZED BLADDER CANCER (2020) (0)
Comparison of Clinicopathological Characteristics, Gene Expression Profiles, Mutational Analysis, and Clinical Outcomes of Pure and Mixed Small Cell Carcinoma of the Bladder. (2023) (0)
Phase I S tudy o f R ecombinant H uman E ndostatin i n Patients W ith A dvanced S olid T umors (2002) (0)
Abstract 5172: Forerunner genes contribute to bladder carcinogenesis by altering the basal to luminal urothelial transition program (2016) (0)
PHP41 THE CHANGING LANDSCAPE OF ORPHAN DRUG PROVISION IN THE EU5 AND THE UNITED STATES (2011) (0)
Abstract IA21: Intravesical gene therapy for NMIBC (2020) (0)
Abstract 4837: Integrated genome sequence, epigenome, and transcriptome map of bladder cancer development (2011) (0)
Abstract 5256: Mechanism of field cancerization (2014) (0)
PANCREATIC CANCER CELLS HAVE REDUCED RESPONSES TO ER STRESS (2008) (0)
Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature (2023) (0)
Decision letter: Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer (2018) (0)
MP72-06 THE LONG NON-CODING RNA SNHG18 PROMOTES PPARγ FUNCTION AND “LUMINAL” GENE EXPRESSION IN MUSCLE-INVASIVE BLADDER CANCER (2015) (0)
Adenovirus-mediated IFNa-2b gene expression is a potent suppressor of proangiogenic factors in bladder cancer cells (2004) (0)
A NOVEL ACTIVATOR OF THE ORPHAN NUCLEAR RECEPTOR Nurr1 INHIBITS BLADDER TUMOR GROWTH (2008) (0)
Abstract 4809: Validation of molecular subtypes of urothelial carcinoma of bladder in multi-institutional and public cohorts (2015) (0)
Abstract LB-317: Anti-invasive effects of saracatinib in preclinical models of luminal bladder cancer (2018) (0)
MP17-14 MOLECULAR CHARACTERIZATION AND RESPONSE TO THE IMMUNOTHERAPY OF SMALL CELL BLADDER CANCER (2020) (0)
Abstract 4098: COX-2 expression in human pancreatic cancer cells is associated with an epithelial phenotype (2012) (0)
MP61-19 A NOVEL ROLE OF THE TRANSCRIPTION FACTOR TCF21 AS A SUPPRESSOR OF BLADDER CANCER METASTASIS (2014) (0)
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434 – 5 (2019) (0)
HumanMena + 11 a IsoformServes as aMarker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines (2008) (0)
Immune modulation by combination type I interferon and checkpoint blockade therapy in murine urothelial carcinoma (2018) (0)
SILENCING OF RELA/P65 ENHANCES TRAIL BUT NOT GEMCITABINE MEDIATED APOPTOSIS IN PANCREATIC CANCER CELLS (2006) (0)
MP83-20 AN ASSESSMENT OF IMMUNE CHECKPOINT EXPRESSION AMONG PATIENTS WITH NMIBC UNDERGOING INTRAVESICAL BCG: IMPLICATIONS FOR ONGOING RANDOMIZED TRIALS. (2018) (0)
The proteasome inhibitor bortezomib reverses TRAIL resistance in refractory human bladder tumors in vivo (2006) (0)
The CD 3 ~ " Cytoplasmic Domain Mediates CD 2-induced T Cell . Activation By (2003) (0)
Extraction-Free Comprehensive Transcriptome Sequencing of Carcinoma In-situ is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer (2020) (0)
MP06-11 MAGNITUDE OF STING SIGNALING DETERMINES ANTITUMOR OUTCOMES, AND CD8+ T CELL MEMORY BY BCG-STING IN UROTHELIAL TUMORS (2022) (0)
Extent of neutrophil (NTP) infiltration in benign lymph nodes (LNs) to predict survival in patients with muscle-invasive bladder cancer (MIBC). (2013) (0)
Integrated oral poster session 1: Wed 2/7 5:00 pmOncology VIII: Clinical outcomeP78: In vitro epithelial mesenchymal transition status predicts gefitinib sensitivity in pancreatic adenocarcinoma cell lines (2007) (0)
MP55-18 SARCOMATOID UROTHELIAL CARCINOMA: CLINICO-PATHOLOGICAL ANALYSIS OF 93 CASES WITH EMPHASIS ON PT1 OUTCOMES IN PATIENTS WHO UNDERWENT EARLY CYSTECTOMY AND/OR NEOADJUVANT CHEMOTHERAPY (2020) (0)
Abstract 3093: Prognostic value of novel immune basal subtypes in muscle invasive bladder cancer (2019) (0)
PI-06 TCF21, A NOVEL METASTASIS SUPPRESSOR, PROMOTES THE ACQUISITION OF A LUMINAL PHENOTYPE IN HUMAN BLADDER CANCER (2015) (0)
MP21-12 WITHDRAWN: A PPARGAMMA-CHOP TRANSCRIPTIONAL NETWORK CONTROLS DIFFERENTIAL EGFR VERSUS FGFR3 DEPENDENCY IN HUMAN BLADDER CANCER CELLS. (2014) (0)
Prediction of survival in patients with muscle-invasive bladder cancer (MIBC) by neutrophil (NTP) infiltration in benign lymph nodes (LNs). (2013) (0)
Genomic analysis of same-patient metachronous upper-tract and bladder urothelial carcinoma. (2018) (0)
MP59-01 URINE MICRORNAS AS LIQUID BIOPSY ASSAY FOR PREDICTING RESPONSE TO INTRAVESICAL BCG THERAPY (2022) (0)
Abstract 4578: Identification of a gene expression signature that is associated with dependency on FGFR3 rather than EGFR in bladder cancer cells (2012) (0)
PD15-12 BLADDER CANCER CIRCULATING TUMOR CELL CONCENTRATION FLUCTUATES IN THE ABSENCE OF SYSTEMIC THERAPY OR SURGERY (2018) (0)
INTRAVESICAL BCG INDUCES CD4+ T CELL EXPANSION BUT NOT ACTIVATION IN A CLINICALLY RELEVANT IMMUNE COMPETENT MODEL OF BLADDER CANCER: MP65‐06 (2017) (0)
Caspases (2003) (0)
PS1145, a novel nuclear factor-kappa B inhibitor, downregulates the proangiogenic factor Interleukin-8 in human bladder cancer cells (2005) (0)
PD12-03 INTERFERON α GENE THERAPY ALTERS TUMOR METABOLISM IN BLADDER CANCER (2022) (0)
CD 3 C dependence of the CD 2 pathway of activation in T lymphocytes and natural killer cells ( sial transduction / acceory moecul / inereukln 2 productlon / Ca 2 + mobilization ) (0)
1070 MICRORNA 200C EXPRESSION PREDICTS OVERALL SURVIVAL AFTER RADICAL CYSTECTOMY (2012) (0)
IMMUNE CORRELATES OF PATHOLOGIC RESPONSE IN BLADDER CANCER PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY: MP88‐11 (2017) (0)
"Advancing bladder preservation: Biomarkers, decision-making, and therapy". (2021) (0)
Abstract 612: Control of the Basal Molecular Subtype of Murine Bladder Cancer by Adaptive Immunity (2023) (0)
Practical Issues With Correlative Studies (2018) (0)

This paper list is powered by the following services:

David James Mcconkey's Academic­Influence.com Rankings

David James Mcconkey's Degrees

Why Is David James Mcconkey Influential?

David James Mcconkey's Published Works

Published Works

David James Mcconkey's AcademicInfluence.com Rankings